EGFR and neoplasm: Among patients with an RAS-Mut tumor, 1.1% received EGFR inhibitors and 59.7% received VEGF inhibitors and, among those with a BRAF-Mut tumor, 6.3% received EGFR inhibitors and 57.2% received VEGF inhibitors.